Medical Devices & Supplies - Specialty (Neurosurgery, Wound Care, Reconstructive Surgery)
Strategic Profile
Integra is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The company expects flat to low single-digit growth in its Codman Specialty Surgical segment and low to mid-single-digit growth in its Tissue Tech segment for 2026.
Cyborg Score Rationale
The company recorded a $511M goodwill impairment in 2025 and reported a GAAP net loss for the year; leverage remains elevated (net debt ~ $1.6B, ~4.5x leverage), which raises capital-allocation and downside risk concerns. Profitability metrics indicate challenges, with a negative EPS of -6.46 and a net margin of -30.15%.
Top Insights
Q4 results exceeded expectations with adjusted EPS of $0.83 topping consensus of $0.79; management highlighted operational progress and a simplified operating model expected to deliver $25–$30M of savings in 2026.
Company continues to see strong demand across both business segments, with strong momentum expected on Integra Skin to drive full year growth expectations.
International business saw strong double-digit performance in China and Canada, expected to continue as a strong growth contributor in 2026 and beyond.
Warning signs include an Altman Z-Score of 0.66, placing the company in the distress zone, and a Piotroski F-Score of 3, indicating poor business operations.
Named Competitors
Spinal Fusion & Orthopedic Devices — Major competitor in neurosurgery and spine markets
Surgical Instruments & Regenerative Medicine — Competitor in orthopedic reconstruction and tissue regeneration
Neurosurgical Devices — Competitor in surgical navigation and neurosurgical instruments